Information

Resilience PRO is indicated for monitoring cancer patients, enabling analysis of the overall evolution of bio-medical dynamics with the aim of detecting progression, recurrence or therapeutic toxicity.
‍
Resilience PRO is a Class IIa Medical Device bearing the CE mark under the regulations.
‍

Documents

Brochure

available here

Support

For any support concerning the use of the service, please contact us by e-mail: support@resilience.care

Resilience PRO

Resilience PRO provides follow-up and support for cancer patients. Whatever the cancer, whatever the stage, whatever the treatment. A unique approach in Europe.

Resilience PRO is a software package for remote monitoring of cancer patients.

Resilience PRO enables automatic detection of relapses or complications linked to therapies. It claims to improve patient quality of life, and extend overall survival.
‍
This is a Class IIa Medical Device declared to the ANSM, designed within the framework of ISO 13 485 certified procedures.
‍
Resilience PRO is an independent French company that has accompanied over 500,000 patients since 2013.
‍

Functionalities

Reliable and secure, Resilience PRO assists caregivers in the remote management of their patients thanks to three main functions:

01
Remote monitoring

Resilience PRO makes it possible to monitor patients remotely and better adapt their care.

02
Detection

Resilience PRO helps caregivers detect relapses and manage complications of therapy.

03
Support

Resilience PRO enables remote therapeutic patient education and optimizes supportive care.

For patients

Patients are sent a weekly questionnaire by SMS to report their symptoms in a few minutes.

The questionnaire can also be received by e-mail.

For caregivers

The data is analysed and if any anomalies are detected, an alert is sent by e-mail.

The care team can access a clear table at any time to understand the patient’s health status and how it changed over the last few weeks.

This allows the care to be adapted if necessary.

Additional feature: therapeutic patient education

Patients have access to therapeutic education content adapted to their reported symptoms and pathology, to help them better understand what they should do and can do on a daily basis.

This reduces the burden on care teams and allows them to focus on patients who require more comprehensive support.

Tomorrow in your care facility.

No installation, no configuration. Deployable as a standalone version in just a few hours.

Compatible with patient portals.
Can be fully integrated into the services you already offer.

Easy interconnection with your EHR. No multiplication of tools: just improvement of existing ones.

Clinical evidence

Improvement in overall survival

+ 5.2 months

31.2 months [24.5-39.6] in the PRO follow-up group
26.0 months [22.1-30.9] in conventional follow-up group

Allows better assessment of symptoms

50%

of symptoms are not detected by conventional monitoring

Impact on quality of life after treatment

31%

of patients in the PRO follow-up group reported a benefit in terms of quality of life compared to the conventional follow-up group.

The Resilience PRO algorithm has been designed on the basis of a comprehensive clinical evaluation, drawing on numerous international publications.

Basch E,Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017;318(2):197-198.
Laugsand EA, Sprangers MAG, Bjordal K, et al. Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes. 2010;8:104.
Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21:1159-1164.
Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014; 32:1480-1501.
Howell D, Molloy S, Wilkinson K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26:1846-1858.
Denis F, Basch E, Septans AL, et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. JAMA. 2019;321(3):306-307
Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2016;34(6):557-565.

Conformity

Resilience PRO meets the most stringent regulatory requirements in terms of quality and safety.

Class IIa Medical Device

Resilience PRO is a Class IIa Medical Device,
registered with the ANSM,
bearing the CE mark.

ISO 13485 certification

We’re certified by GMED as meeting the requirements of the international standard ISO 13485.

Security – PGSSI-S

We’re aligned with the requirements of PGSSI-S / ISO 27001: the safety of patients and the security of their data is ensured.

Data – GDPR

We comply with the GDPR requirements on data processing and the provision of good information to our users.

Would you like to know more?

Send us an e-mail and our team will contact you as soon as possible:
bonjour@resilience.care

Name: Resilience PRO
‍
Indication: The Resilience PRO device is a monitoring and clinical decision support software in the field of oncology. It is intended for remote monitoring of cancer patients by healthcare professionals, outside emergency situations.

Date of last modification: V2.0.0, 19.11.2020

Regulatory information

The Resilience solution includes the Resilience PRO remote monitoring module, indicated for monitoring cancer patients, by enabling the monitoring of adverse events in order to decide on the need to adapt the patient's management. This Class Iia medical device is a regulated healthcare product, bearing the CE 04959 mark. Manufactured by Resilience MD, Resilience PRO is a medical device reimbursed by the French Assurance Maladie. Please read the instructions carefully.
Resilience, RCS of Paris under number 893 834 713

This medical device is a regulated health product which carries, under this regulation, the CE marking
All users are invited to read, before any first use, the instructions for use made available to them.
‍‍

‍If you have any questions or require assistance, please contact support by e-mail: support@resilience.care

‍

2013 - 2023 Resilience MD
legal notice - privacy policy
‍